NCT05386472View on ClinicalTrials.gov

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

March 26, 2025

Study Completion Date

May 12, 2025

Conditions
COVID-19
Interventions
DRUG

nirmatrelvir

Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)

DRUG

ritonavir

Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)

Trial Locations (13)

32713

Omega Research Debary, DeBary

32808

Omega Research Orlando, Orlando

33157

Beautiful Minds Clinical Research Center, Cutler Bay

33615

Santos Research Center, Tampa

35233

University of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham

59804

Boeson Research MSO, Missoula

Origin Health, Missoula

77573

Maximos Ob/Gyn, League City

83404

Clinical Research Prime, Idaho Falls

84108

University of Utah, Salt Lake City

84112

University of Utah, Salt Lake City

84132

University of Utah Clinical Neuroscience Center, Salt Lake City

University of Utah Hospital, Salt Lake City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05386472 - A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 | Biotech Hunter | Biotech Hunter